Evidence map›Paper›PMID 20430016›Full record

ReviewChemico-biological interactions2010

Chromium genotoxicity: A double-edged sword.

Kristen P Nickens, Steven R Patierno, Susan Ceryak

Abstract readReview
In one paragraph

Review in Chemico-biological interactions, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Unravelling the developmental toxicity of heavy metals using zebrafish as a model: a narrative review.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Review
  11. Review
  12. Toxicology reports · 2024
    Article
  13. Review
  14. A timely update on g-CRSC advances · 2024
    Review
  15. Review
  16. Review
  17. Review
  18. Metabolic Carcinogenesis.Cancer treatment and research · 2024
    Review
  19. Review
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kristen P NickensDepartment of Pharmacology and Physiology, The George Washington University Medical Center, Washington, DC 20037, United States.
Steven R Patierno
Susan Ceryak

Funding

PARTICULATE CHROMIUM TOXICITY AND CARCINOGENESISR01ES005304 · NIEHS · GEORGE WASHINGTON UNIVERSITY · PI PATIERNO, STEVEN R · 1990 to 2007
$2.6M
Survival Signaling After Genotoxic InsultR01CA107972 · NCI · GEORGE WASHINGTON UNIVERSITY · PI CERYAK, SUSAN M · 2005 to 2009
$1.4M
PARTICULATE CHROMIUM TOXICITY AND CARCINOGENESISR01ES009961 · NIEHS · GEORGE WASHINGTON UNIVERSITY · PI PATIERNO, STEVEN R · 2000 to 2003
$1.4M
Mechanisms of particulate chromium lung carcinogenesisR21ES017334 · NIEHS · GEORGE WASHINGTON UNIVERSITY · PI CERYAK, SUSAN M · 2010 to 2011
$428k
NCI NIH HHS R01 CA107972NCI NIH HHS R01CA107972NIEHS NIH HHS R01 ES005304NIEHS NIH HHS R01 ES009961NIEHS NIH HHS R01ES05304NIEHS NIH HHS R01ES09961NIEHS NIH HHS R21 ES017334
6 · The paper itself

Abstract

Certain forms of hexavalent chromium [Cr(VI)] are known respiratory carcinogens that induce a broad spectrum of DNA damage. Cr(VI)-carcinogenesis may be initiated or promoted through several mechanistic processes including, the intracellular metabolic reduction of Cr(VI) producing chromium species capable of interacting with DNA to yield genotoxic and mutagenic effects, Cr(VI)-induced inflammatory/immunological responses, and alteration of survival signaling pathways. Cr(VI) enters the cell through non-specific anion channels, and is metabolically reduced by agents including ascorbate, glutathione, and cysteine to Cr(V), Cr(IV), and Cr(III). Cr(III) has a weak membrane permeability capacity and is unable to cross the cell membrane, thereby trapping it within the cell where it can bind to DNA and produce genetic damage leading to genomic instability. Structural genetic lesions produced by the intracellular reduction of Cr(VI) include DNA adducts, DNA-strand breaks, DNA-protein crosslinks, oxidized bases, abasic sites, and DNA inter- and intrastrand crosslinks. The damage induced by Cr(VI) can lead to dysfunctional DNA replication and transcription, aberrant cell cycle checkpoints, dysregulated DNA repair mechanisms, microsatelite instability, inflammatory responses, and the disruption of key regulatory gene networks responsible for the balance of cell survival and cell death, which may all play an important role in Cr(VI) carcinogenesis. Several lines of evidence have indicated that neoplastic progression is a result of consecutive genetic/epigenetic changes that provide cellular survival advantages, and ultimately lead to the conversion of normal human cells to malignant cancer cells. This review is based on studies that provide a glimpse into Cr(VI) carcinogenicity via mechanisms including Cr(VI)-induced death-resistance, the involvement of DNA repair mechanisms in survival after chromium exposure, and the activation of survival signaling cascades in response to Cr(VI) genotoxicity.

Indexed as

AnimalsCarcinogensCell DeathCell SurvivalChromiumDNA DamageDNA RepairHumansMutagensCarcinogensChromiumMutagens

Identifiers

PMID20430016
PMCPMC2942955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.